GoodRx Holdings (GDRX) Sets Q2 Results Date, Is The Stock Still Undervalued?

GoodRx Holdings (GDRX) has scheduled the release of its second quarter results for August 5, 2026, after the market close, followed by a conference call and webcast on August 6.

See our latest analysis for GoodRx Holdings.

GoodRx Holdings’ recent share price has moved to US$2.95, with a 30 day share price return of 15.23% and a 90 day share price return of 34.70%. However, the 1 year total shareholder return is down 37.83%, pointing to improving short term momentum against a weaker long term experience.

If this earnings update has you thinking about where else growth or re rating potential could show up in healthcare, it may be worth scanning 41 healthcare AI stocks

GoodRx Holdings sits between a widely used healthcare platform and a share price that has climbed in recent months but remains well below longer term levels. How does that trade off look when you focus purely on valuation next?

Most Popular Narrative: 7.3% Undervalued

GoodRx Holdings is trading at $2.95 versus a narrative fair value of $3.18, putting the spotlight on what assumptions sit behind that gap.

Substantial momentum in the company's pharma manufacturer solutions (32% YoY revenue growth, with management projecting 30%+ in 2025) reflects strong demand for direct-to-patient engagement, unlocking higher-margin revenue streams and providing meaningful upside to consolidated revenue and net margins.

Read the complete narrative.

Curious what kind of revenue mix, margin profile, and earnings run rate need to line up to justify that valuation? The most followed GoodRx Holdings narrative spells it out step by step, using specific growth and profitability paths rather than vague optimism.

Result: Fair Value of $3.18 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the GoodRx Holdings narrative can still be knocked off course if pharmacy benefit manager decisions reshape programs like Integrated Savings or if larger competitors bypass its pricing tools.

Find out about the key risks to this GoodRx Holdings narrative.

Next Steps

With mixed signals around GoodRx Holdings, you do not need to wait to see how sentiment settles. You can review the balance of potential upsides and concerns yourself and then weigh the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond GoodRx Holdings?

If you are weighing what to do next after GoodRx Holdings, do not sit on the sidelines while other opportunities line up across different styles, sectors, and risk profiles.

• Target potential value opportunities early by scanning 44 high quality undervalued stocks for stocks that combine strong fundamentals with prices that may not fully reflect their underlying strength.
• Build a steadier income stream by reviewing 9 dividend fortresses focused on companies with higher dividend yields that may appeal if you want cash returns alongside price moves.
• Prioritise resilience by checking 76 resilient stocks with low risk scores so you can focus on stocks that score better on risk and might help balance out more aggressive positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com